Preprint Concept Paper Version 1 Preserved in Portico This version is not peer-reviewed

Analyzing the Distribution of Mutations for Glycogen Storage Disease Type 1a in Turkey and Suggested Gene Therapy Methods for Its Treatment

Version 1 : Received: 28 September 2020 / Approved: 30 September 2020 / Online: 30 September 2020 (08:05:17 CEST)

How to cite: Mantas, A.; Ucaryilmaz, C.; Demir, B.S.; Guler, F.N.; Mengi, S.; Inci, C.C.; Kilic, O.; Babar, H.A.; Ceylaner, G.; Ceylaner, S.; Tastan, C. Analyzing the Distribution of Mutations for Glycogen Storage Disease Type 1a in Turkey and Suggested Gene Therapy Methods for Its Treatment. Preprints 2020, 2020090723 (doi: 10.20944/preprints202009.0723.v1). Mantas, A.; Ucaryilmaz, C.; Demir, B.S.; Guler, F.N.; Mengi, S.; Inci, C.C.; Kilic, O.; Babar, H.A.; Ceylaner, G.; Ceylaner, S.; Tastan, C. Analyzing the Distribution of Mutations for Glycogen Storage Disease Type 1a in Turkey and Suggested Gene Therapy Methods for Its Treatment. Preprints 2020, 2020090723 (doi: 10.20944/preprints202009.0723.v1).

Abstract

One of the rare diseases throughout the world is Glycogen Storage Disease, which appears due to problems in glycogen metabolism. Among various subtypes of GSD, GSD Type 1a is the most abundant one of GSD Type 1, seen in approximately 80% and caused by different kinds of mutations in the Glucose-6-Phosphatase Catalytic Subunit (G6PC) gene in human chromosome 17q21. G6PC gene encodes for glucose-6-phosphatase (G6Pase) protein, which cleaves glucose-6-phosphate into glucose and inorganic phosphate (Pi), and GSD Type 1a patients fail to breakdown glucose-6-phosphate due to several mutations in the G6PC gene. In our study, we aim to create new therapeutic approaches for GSD 1a. We collected mutation data of 57 GSD Type 1a patients from Turkey. According to the data, 16 types of mutations were observed in the G6PC gene. Allele frequencies of these mutations are calculated as 59% for R83C/H, 11% for W160*, 7% for G270V, and 28% for others which have less frequency. Up to now, the tertiary protein structure of G6Pase has not been structured yet. To understand the possible impacts of these mutations, we statistically obtained possible tertiary structure predictions of G6Pase by running 5 different tools. At the end of the study, we suggest two effective and promising gene therapy methods for GSD Type 1a, Prime Editing for R83C/H mutations, and mRNA delivery for other mutations, in addition to a promising, commercially available drug suggestion for patients with W160*, W86*, and S15* mutations, although the drug belongs to another disease.

Subject Areas

Glycogen Storage Disease Type 1a, Glucose-6-phosphatase Catalytic Subunit (G6PC), Glucose-6-phosphatase (G6Pase), prime editing, mRNA delivery, CRISPR

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.